TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHAMP App
Description: CHAMP® App is a proprietary, downloadable, mobile Software Application and software platform designed and developed by the Children's Mercy Hospital of Kansas City (CMH), that permits parents and caregivers to transmit to the care team data to permit remote monitoring of the patient's condition. The parent or caregiver enters into the CHAMP App data including vital signs, intake and output, video, and images of patients (collectively, CHAMP® Data), which operates on computers, mobile devices, and handheld computers. The CHAMP® App is intended to be used in the clinical care of pediatric patients in the home setting that are followed by specialty health care teams to improve patient self-management through the use of asynchronous data. Videos and data related to the patient are entered by the parent and sent electronically to the Clinical Care Team as recommended by the clinical team.
Study: NCT05527717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culprit lesion only PCI
Description: Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate multi-vessel PCI
Description: Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI.
Study: NCT06676384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone and SoC
Description: Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
Study: NCT05819736

Intervention type: OTHER
Intervention: Monitoring
Description: Monitoring
Study: NCT05946902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron
Description: mirabegron 25 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine , mirabegron
Description: tolterodine 4 mg and mirabegron 25 mg per day
Study: NCT06676384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gut-directed budesonide and SoC
Description: Gut-directed Budesonide 12 mg once daily for nine months and tapered to 9mg once daily for the next three months, 6mg once daily for the next three months and 3mg once daily for the next three months and stopped (total 18 months). All participants in this arm will receive SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and SoC
Description: Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and SoC
Description: Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months. All participants in this arm will receive SoC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal mineralocorticoid receptor antagonist and SoC
Description: Generic drug not available currently. All participants in this arm will receive SoC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Description: Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).
Study: NCT06676839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the complete ICOPE program
Description: The participant benefits from a personalized intervention, including 1) a screening to be repeated every 6 months, based on the use of the ICOPE tool, allowing an assessment of the 6 functions necessary for an autonomous lifestyle; 2) a comprehensive assessment step for the 6 functions 3) a personalized intervention step aimed at correcting the trajectory of functional decline, based on the participants' preferences; 4) a follow-up step for this intervention.~Participants will benefit from telephone follow-up 1.5 months after the start of the program and between each annual visit to support them in implementing their personalized intervention plan.~At each contact, the ICOPE nurse reviews the participant's implementation of the personalized intervention plan recommendations and their adherence to the program.~The results of the assessment and the proposed intervention are communicated and discussed with the primary care physician and a summary letter is also sent.
Study: NCT06677424

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroCatch® Platform 2
Description: The NeuroCatch® Platform 2, a medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information. The device is approved as a medical device by Health Canada.
Study: NCT06677385

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: diode laser as adjunctive to conventional scaling and debridement
Description: diode laser as adjunctive to conventional scaling and debridement for old age patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: diode laser as adjunctive to conventional scaling and debridement
Description: diode laser as adjunctive to conventional scaling and debridement for old age patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional scaling and debridement
Description: conventional scaling and debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional scaling and debridement
Description: conventional scaling and debridement
Study: NCT06677255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VUM02 Injection (UC-MSCs)+BAT
Description: The dose-escalation phase (phase I):~Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week.~The dose-expansion phase (phase II):~-Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses.

Intervention type: OTHER
Group type: OTHER
Intervention: The control group with Best Available Therapy (BAT)
Description: According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
Study: NCT05832086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (FMD)
Description: Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Anti-Cancer Diet
Description: Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
Study: NCT05251207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine-L-tartrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine-L-tartrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: L-carnitine-L-tartrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-leucine
Description: L-leucine
Study: NCT06013059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three levels of TMJ arthroscopy
Description: Group I: 10 patients will be treated with Lysis and lavage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three levels of TMJ arthroscopy
Description: Group II: 10 patients will be treated with operative arthroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three levels of TMJ arthroscopy
Description: Group III: 10 patients will be treated with operative arthroscopy + discopexy
Study: NCT05251207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-leucine
Description: L-leucine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change of the circadian cycle
Description: Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change of the circadian cycle
Description: Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
Study: NCT06676787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transportation Voucher, Comunity engagement and microplannnig support
Description: Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. This is in addition to support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Facility Funding, Community Engagement, and Microplaning Support
Description: Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly performance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support
Description: Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly oerformance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
Study: NCT06677125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Mallet
Description: The osteotome will be directly attached and pushed by magnetic mallet and a shock wave will be pushed on their tip. The electrical mallet will be imparted to osteotomes a longitudinal movement along a central axis moving up and down toward pilot bone hole providing a driving mechanism of longitudinal movements. Then the sinus lift instruments (Sweden and Martina) will be used to slowly lift the sinus. After that implant will be placed with the help of implant drilling device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Densah bur
Description: The implant motor will be adjusted on reverse-densifying mode with 800 to 1200 rpm. According to the desired implant dimension, it will be started with the smallest densah bur. The first densah bur will advanced in densifying mode with bouncing motion in and out movement with copious irrigation until.
Study: NCT04484701

Intervention type: DRUG
Intervention: 68Ga-PSMA-11
Description: PET/CT scan with radiotracer 68Ga-PSMA-11
Study: NCT04870645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Magnetic Resonance Imaging
Description: Undergo advanced MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo conventional MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-Chelate
Description: Contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: Contrast agent
Study: NCT06014775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 antibody Injection
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study: NCT06139315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765845
Description: BI 765845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05289466

Intervention type: RADIATION
Group type: OTHER
Intervention: Intraoperative Radiotherapy
Description: Intraoperative Radiotherapy (Xoft, 20 Gy single dose)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oncoplastic partial mastectomy
Description: Breast Conserving Therapy
Study: NCT05017571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1 capsule (0.6 mg) per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1 capsule (0.6 mg) per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule per day
Study: NCT05913141

Intervention type: OTHER
Intervention: Drug screen with PDO/PDO-TIL/PDOTS
Description: Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
Study: NCT05896618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPA
Description: 1. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nance appliance
Description: 2. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
Study: NCT05890313

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination
Description: MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination
Description: MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Description: MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain on Track (version BOT.0.0.0 03.03.2023)
Description: Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
Study: NCT04621006

Intervention type: DIAGNOSTIC_TEST
Intervention: Continuously assessment of disease activity
Description: Continuous measures of disease activity and activity in the contact activation system.
Study: NCT05739877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (After)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 2.5/500mg (After)
Description: single dose administration (one tablet once a day)
Study: NCT05526859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinsiotaping for wrist flexor muscles
Description: The flexor muscles of the wrist area will be targeted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping for wrist extensor muscles
Description: The extensor muscles of the wrist area will be targeted.
Study: NCT05510778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Charcocaps
Description: 250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules containing \~250 mg cellulose
Study: NCT04940442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach
Description: Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach
Description: Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
Study: NCT06169930

Intervention type: OTHER
Intervention: This was an observational study without any intervention
Description: This was an observational study without any intervention

Intervention type: OTHER
Intervention: This was an observational study without any intervention
Description: This was an observational study without any intervention
Study: NCT05678075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole-food plant-based nutrition education
Description: Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
Study: NCT05319080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.